Analysis of Immunogenicity of Intracellular CTAR Fragments of Epstein—Barr Virus Latent Phase Protein LMP1 by Lomakin Y. et al.
766
0007­-4888/17/16360766­­©­2017­­Springer­Science+Business­Media­New­York
Analysis of Immunogenicity of Intracellular CTAR Fragments 
of Epstein—Barr Virus Latent Phase Protein LMP1
Ya. A. Lomakin1,2, A. A. Shmidt1, T. V. Bobik1,2, A. S. Chernov3,  
A. Yu. Pyrkov1, N. M. Aleksandrova2, D. O. Okunola2, M. I. Vaskina1,  
N. A. Ponomarenko1, G. B. Telegin3, M. V. Dubina4, and A. A. Belogurov Jr1,2
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 163, No. 6, pp. 732-737, June, 2017
Original article submitted November 1, 2016
Intracellular fragments of latent phase protein LMP1 of Epstein—Barr virus, denoted as 
CTAR1/2/3, can trigger a variety of cell cascades and contribute to the transforming potential 
of the virus. Generation of recombinant proteins CTAR1/2/3 is expected to yield more ample 
data on functional and immunogenic characteristics of LMP1. We created genetic constructs 
for prokaryotic expression of LMP1 CTAR fragments and selected optimal conditions for 
their production and purification. Using a new library of LMP1 CTAR fragments, we carried 
out epitope mapping of a diagnostic anti-LMP1 antibody S12. Analysis of polyclonal serum 
antibodies from mice immunized with full-length LMP1 confirmed immunogenicity of CTAR 
elements comparable with that of full-length protein
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Latent membrane protein 1 (LMP1) is one of the most 
intensely studied and mysterious proteins of Epstein—
Barr virus (EBV). According to various estimations, 
EBV infects 80-95% adult population of the planet and 
the infection is asymptomatic in the majority of cases. 
However, disturbed balance of lythic (productive) and 
latent (nonproductive) phases in viral life cycle can 
lead to grave diseases with serious complications. 
EBV is associated with many autoimmune diseases, 
such as multiple sclerosis [4,6], rheumatoid arthritis 
[3], and systemic lupus erythematosus [9]. The rela-
tionship between the virus and lymphoid and epithelial 
carcinomas, such as Burkitt’s lymphoma, Hodgkin’s 
lymphoma, nasopharyngeal carcinoma, and EBV-as-
sociated gastric carcinoma, is even more evident [8].
The virus infects mainly B cells and to a lesser 
extent T cells, epithelial, and NK cells. A specific fea-
ture of B and T cell infection is cell immortalization 
followed by their reactivation. In most cases immune 
system controls infection, and virus remains in latent 
form in the infected cells throughout all human life. 
The main reservoir for EBV are the long-living B-
memory cells that passed stage of somatic hypermuta-
tion [12]. During the latent phase, infected cells pro-
duce a set of EBV genes, including 6 nuclear proteins 
(EBNA-1/2/3A/3C/LP), minor RNA (EBER-1/2), and 
membrane proteins (LMP-1/2A/2B). These proteins 
control cell cycle, allowing the infected cells to escape 
apoptosis.
The main transducer protein of EBV, LMP1, acts 
as a classical oncogene on model rat fibroblasts and is 
essential for EBV-dependent B-cell transformation in 
vitro [15]. LMP1 functions as a constantly activated 
TNF receptor in ligand-independent manner. Func-
tionally, LMP1 mimics CD40 and can even partially 
substitute it in vivo, providing growth and differential 
signals to B cells [13]. LMP1 is a polypeptide con-
sisting of 386 amino acids with a molecular weight 
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